SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy

SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.

SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy

On February 26, 2026, SCYNEXIS, Inc. (NASDAQ:SCYX) announced that the first participants had been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of its second-generation triterpenoid antifungal therapy, SCY-247. The therapy is being developed as a treatment for invasive candidiasis and as a prophylaxis therapy for invasive fungal disease, with results from the trial expected in 2026.

Earlier, SCYNEXIS, Inc. (NASDAQ:SCYX) said that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product and Fast Track Designations for SCY-247. Further, SCYNEXIS, Inc. (NASDAQ:SCYX) said that it expects to initiate a Phase 1 study of the intravenous formulation and a Phase 2 study of the oral formulation in invasive candidiasis during 2026, and plans to release proof-of-concept data for the oral formulation the same year.

SCYNEXIS, Inc. (NASDAQ:SCYX) said it will also explore potential non-dilutive funding opportunities to support development of the program as antifungal resistance continues to emerge.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company focused on developing medicines to treat and prevent difficult-to-treat and drug-resistant infections.

While we acknowledge the potential of SCYX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SCYX and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.